Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.71 USD | +2.45% | -0.65% | -46.63% |
23/04 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
22/04 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
Sales 2024 * | 967M 80.65B | Sales 2025 * | 1.09B 90.78B | Capitalization | 2.75B 230B |
---|---|---|---|---|---|
Net income 2024 * | 110M 9.17B | Net income 2025 * | 221M 18.43B | EV / Sales 2024 * | 2.22 x |
Net cash position 2024 * | 606M 50.57B | Net cash position 2025 * | 864M 72B | EV / Sales 2025 * | 1.74 x |
P/E ratio 2024 * |
26.6
x | P/E ratio 2025 * |
12.8
x | Employees | 598 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.45% |
Latest transcript on ACADIA Pharmaceuticals Inc.
1 day | +2.45% | ||
1 week | -0.65% | ||
Current month | -9.63% | ||
1 month | -6.07% | ||
3 months | -37.97% | ||
6 months | -25.73% | ||
Current year | -46.63% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 15/14/15 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 28/20/28 |
Benir Ruano
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 11/15/11 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 25/15/25 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 15/14/15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.73% | 1 M€ | 0.00% | - | |
1.24% | 16 M€ | -8.49% | ||
0.26% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 16.71 | +2.45% | 1,168,199 |
25/24/25 | 16.31 | -1.69% | 1,660,634 |
24/24/24 | 16.59 | -0.90% | 1,296,887 |
23/24/23 | 16.74 | -1.47% | 1,476,024 |
22/24/22 | 16.99 | +1.01% | 1,156,988 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.63% | 2.75B | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ACAD Stock